PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32521853-0	2020	Efficacy of albumin-bound paclitaxel in the treatment of advanced refractory breast cancer and its effect on serum resistin.	Paclitaxel	26-36	resistin	Homo sapiens	115-123	
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	71-81	resistin	Homo sapiens	182-190	
32521853-1	2020	PURPOSE: This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin.	Paclitaxel	87-97	resistin	Homo sapiens	182-190	
32521853-9	2020	CONCLUSION: The results indicated that nab-paclitaxel is very effective in treating advanced refractory BC and reduces the level of serum resistin.	Paclitaxel	43-53	resistin	Homo sapiens	138-146